Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (now NewcelX Ltd.) covers the month of October 2025. The report details the finalization of a merger with Kadimastem Ltd., a 1-for-10 reverse share split, and a corporate name change. These actions were approved by shareholders at an Extraordinary General Meeting held on September 29, 2025, and became effective in Switzerland on October 30, 2025.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. Instead, it focuses on the post-transaction capital structure effective October 30, 2025:
- Total Share Capital: CHF 282,908.80 divided into 5,533,183 common shares and 124,993 preferred shares (par value CHF 0.05 each).
- Participation Capital: CHF 3,032.40 divided into 60,648 preferred participation certificates.
- Issued and Outstanding Common Shares: 4,558,378 shares upon effectiveness of the reverse split and merger.
- Issuable Shares: 1,060,574 common shares issuable upon exercise of pre-funded warrants issued as merger consideration.
- Capital Band: Upper limit of CHF 428,911.80 and lower limit of CHF 142,970.60, allowing for the issuance of up to 2,859,412 additional common shares.
- Conditional Share Capital: Includes up to 450,000 common shares (CHF 22,500) and up to 2,409,412 shares (CHF 120,470.60).
Material Changes Versus Prior Period
The primary material change is the structural transformation of the company resulting from the merger with Kadimastem Ltd. and the 1-for-10 reverse split. Key changes include:
- Corporate Name: Changed from NLS Pharmaceutics Ltd. to NewcelX Ltd.
- Share Consolidation: Implementation of a 1:10 reverse split to satisfy Nasdaq listing requirements.
- Capital Increase: Ordinary capital increase via contribution in kind of Kadimastem Ordinary Shares.
- Par Value Reduction: Reduction of par value for common shares, preferred shares, and preferred participation certificates as a preparatory measure for the consolidation.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the approved corporate actions. The filing confirms that the reverse split will be reflected on Nasdaq at market open following its effectiveness in Switzerland on October 30, 2025, with publication in the Swiss Official Gazette of Commerce expected around October 31, 2025. The filing does not contain specific forward-looking guidance on revenue, product development timelines, or liquidity risks beyond the structural changes described.
Investor Verification Checklist
- Verify the effective date of the reverse split and name change on Nasdaq (expected October 30, 2025).
- Confirm the exact number of shares issued to Kadimastem shareholders based on the Exchange Ratio.
- Review the Amended and Restated Articles of Association (Exhibit 99.1) for details on the capital band and conditional share capital.
- Monitor the publication of the reverse split in the Swiss Official Gazette of Commerce.
- Assess the impact of the 1,060,574 pre-funded warrants on future dilution.